Orbimed Advisors LLC Gh Research PLC Transaction History

Orbimed Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$7.88 - $12.74 $7.27 Million - $11.8 Million	-922,700 Reduced 55.62%	736,315 $8.74 Million
Q1 2023 May 15, 2023	BUY	$6.02 - $10.92 $222,469 - $403,548	36,955 Added 2.28%	1,659,015 $13.3 Million
Q2 2022 Aug 15, 2022	BUY	$8.99 - $19.87 $1.74 Million - $3.84 Million	193,328 Added 13.53%	1,622,060 $16.2 Million
Q4 2021 Feb 14, 2022	BUY	$14.1 - $27.9 $930 - $1,841	66 Added 0.0%	1,428,732 $33.3 Million
Q2 2021 Aug 16, 2021	BUY	$19.25 - $21.73 $27.5 Million - $31 Million	1,428,666 New	1,428,666 $31 Million

17M

25.5K

19.8K

Ticker GHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,020,800
Market Cap $611M
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.